Changeflow GovPing Pharma & Drug Safety EPO Patent Publication: Urea or Carbamate Lipid...
Routine Notice Added Final

EPO Patent Publication: Urea or Carbamate Lipid Nanoparticles

Favicon for changeflow.com ChangeBridge: EPO Bulletin - Biotech (C12N)
Published March 18th, 2026
Detected March 24th, 2026
Email

Summary

The European Patent Office (EPO) has published a patent application (EP2026029046A1) concerning urea or carbamate lipids with cyclic groups in the side chain, and related lipid nanoparticles and pharmaceutical compositions. The publication date is March 18, 2026.

What changed

This document is a publication of a European patent application (EP2026029046A1) by the European Patent Office (EPO), dated March 18, 2026. The patent pertains to novel urea or carbamate lipids featuring a cyclic group in their side chain, as well as lipid nanoparticles and pharmaceutical compositions incorporating these lipids. The application includes detailed IPC classifications related to organic chemistry, pharmaceutical compositions, and biotechnology.

As this is a patent publication, it does not impose direct regulatory obligations or compliance deadlines on entities. However, it is relevant for drug manufacturers and pharmaceutical companies operating within the EU, particularly those involved in research and development of lipid-based drug delivery systems. Companies should be aware of this publication for intellectual property and competitive intelligence purposes, especially concerning potential patent infringement or licensing opportunities.

Source document (simplified)

← EPO Patent Bulletin

UREA OR CARBAMATE LIPID HAVING CYCLIC GROUP IN SIDE CHAIN, LIPID NANOPARTICLES THEREOF, AND PHARMACEUTICAL COMPOSITION THEREOF

Publication EP2026029046A1 Kind: A1 Mar 18, 2026

Inventors

The designation of the inventor has not yet been filed

IPC Classifications

C07D 205/04 20060101AFI20260207BHEP A61K 9/127 20250101ALI20260207BHEP A61K 31/7105 20060101ALI20260207BHEP A61K 47/24 20060101ALI20260207BHEP A61K 47/28 20060101ALI20260207BHEP A61K 47/34 20170101ALI20260207BHEP A61K 48/00 20060101ALI20260207BHEP A61P 25/00 20060101ALI20260207BHEP A61P 43/00 20060101ALI20260207BHEP C07D 211/26 20060101ALI20260207BHEP C07D 211/46 20060101ALI20260207BHEP C07D 223/12 20060101ALI20260207BHEP C07D 243/08 20060101ALI20260207BHEP C07D 401/12 20060101ALI20260207BHEP C07D 403/12 20060101ALI20260207BHEP C12N 15/11 20060101ALI20260207BHEP

Designated States

AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR

View original document →

Named provisions

UREA OR CARBAMATE LIPID HAVING CYCLIC GROUP IN SIDE CHAIN, LIPID NANOPARTICLES THEREOF, AND PHARMACEUTICAL COMPOSITION THEREOF

Source

Analysis generated by AI. Source diff and links are from the original.

Classification

Agency
EPO
Published
March 18th, 2026
Instrument
Notice
Legal weight
Non-binding
Stage
Final
Change scope
Minor
Document ID
EP2026029046A1

Who this affects

Applies to
Drug manufacturers Pharmaceutical companies
Industry sector
3254 Pharmaceutical Manufacturing 3254.1 Biotechnology
Activity scope
Drug Development Intellectual Property Management
Geographic scope
European Union EU

Taxonomy

Primary area
Pharmaceuticals
Operational domain
Legal
Compliance frameworks
FDA 21 CFR Part 11
Topics
Intellectual Property Biotechnology

Get Pharma & Drug Safety alerts

Weekly digest. AI-summarized, no noise.

Free. Unsubscribe anytime.

Get alerts for this source

We'll email you when ChangeBridge: EPO Bulletin - Biotech (C12N) publishes new changes.

Free. Unsubscribe anytime.